Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shulifenxiao formula is a traditional Chinese herbal medicine regimen used as an alternative or adjunctive therapy for nephrotic syndrome, particularly in patients with refractory idiopathic membranous nephropathy (RIMN) and primary membranous nephropathy (PMN) who are resistant to corticosteroids and immunosuppressants. The formulation is considered a "clinical cocktail therapy" and has demonstrated efficacy in reducing proteinuria, increasing serum albumin levels, improving estimated glomerular filtration rate (eGFR), and achieving remission in clinical studies. It is often used alone or in combination with low-dose cyclophosphamide. The mechanism of action appears to involve immunomodulation and reduction of anti-phospholipase A2 receptor antibody titers[1][2][3][4]. The safety profile is favorable with few adverse effects reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shulifenxiao formula.